Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Operating Expenses (2021 - 2025)

PAVmed (PAVM) has 5 years of Operating Expenses data on record, last reported at $4.8 million in Q3 2025.

  • For Q3 2025, Operating Expenses changed N/A year-over-year to $4.8 million; the TTM value through Sep 2025 reached $20.2 million, changed N/A, while the annual FY2024 figure was $47.5 million, 33.36% down from the prior year.
  • Operating Expenses reached $4.8 million in Q3 2025 per PAVM's latest filing, up from $4.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $24.8 million in Q4 2022 and bottomed at $4.7 million in Q2 2025.
  • Average Operating Expenses over 5 years is $14.9 million, with a median of $15.7 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 145.44% in 2022, then plummeted 70.18% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $20.0 million in 2021, then grew by 24.01% to $24.8 million in 2022, then dropped by 29.64% to $17.4 million in 2023, then tumbled by 70.18% to $5.2 million in 2024, then dropped by 6.75% to $4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $4.8 million in Q3 2025, $4.7 million in Q2 2025, and $5.5 million in Q1 2025.